Qiu Ling, Lin Jianguo, Nan Beibei, Lv Gaochao, Cheng Wen
Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, PR China.
Pak J Pharm Sci. 2015 May;28(3):815-8.
Developing novel superior bone-seeking radiopharmaceutical for the detection of malignant bone lesions could further improve the diagnostic value of routine bone scanning and shorten the interval between injection and imaging. In order to further evaluate the bone imaging efficiency of (99m)Tc-HBIDP (1-hydroxy-2-(1-butyl-imidazol-2-yl)-ethane-1,1-diphosphonic acid), the pharmacokinetic in mice and single photon emission computed tomography (SPECT) bone scanning in rabbit for (99m)Tc-HBIDP was investigated. Kinetics of blood clearance showed that the distribution half-life (T(1/2a)) and elimination half-life (T(1/2 β)) of (99m)Tc-HBIDP are 2.73 and 24.87 min, respectively. Excellent bone images can be obtained at 1 h post injection with SPECT bone scanning, which is clearer and quicker than (99m)Tc-ZL (zoledronate) and (99m)Tc-MDP (methylenediphosphonate). All results indicate that (99m)Tc-HBIDP holds great potential as a novel improved bone imaging agent.
开发新型的、性能更优的亲骨性放射性药物用于检测恶性骨病变，可进一步提高常规骨扫描的诊断价值，并缩短注射与成像之间的间隔时间。为了进一步评估（99m）Tc-HBIDP（1-羟基-2-（1-丁基-咪唑-2-基）-乙烷-1,1-二膦酸）的骨显像效率，研究了其在小鼠体内的药代动力学以及在兔体内的单光子发射计算机断层扫描（SPECT）骨显像。血液清除动力学表明，（99m）Tc-HBIDP的分布半衰期（T（1/2a））和消除半衰期（T（1/2β））分别为2.73分钟和24.87分钟。注射后1小时进行SPECT骨扫描可获得优质的骨图像，比（99m）Tc-ZL（唑来膦酸）和（99m）Tc-MDP（亚甲基二膦酸盐）更清晰、更快。所有结果表明，（99m）Tc-HBIDP作为一种新型的改良骨显像剂具有巨大潜力。
Zotero 插件